William Blair launched coverage of Calithera Biosciences (NASDAQ:CALA) with an “outperform” rating. The stock closed at $16.05 on Oct. 5.Read More
Maxim Group raised its price target for BeiGene (NASDAQ:BGNE) to $120 from $77 after the company announced preliminary data from its ongoing Phase 1/2 study of BGB-A317 (PD-1 antibody) in Chinese patients with advanced solid tumors at the 20th annual meeting of the Chinese Society of Clinical Oncology in Xiamen, China.Read More
The National Health Service (NHS) Scotland-sponsored Early Cancer Detection Test – Lung Cancer Scotland (ECLS) study of 12,000 high-risk smokers has demonstrated additional, positive, early detection of lung cancer with the use of the EarlyCDT-Lung test.Read More
Leerink launched coverage of Mersana Therapeutics (NASDAQ:MRSN) with an “outperform” rating and $23 one-year price target, representing an approximate $500-million valuation. The stock closed at $14.05 on July 21.Read More
Ladenburg Thalmann launched coverage of Leap Therapeutics (NASDAQ: LPTX) with a “buy” rating and $18 price target. The stock closed at $7.85 on March 6.Read More
H.C. Wainwright initiated coverage of OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) with a “buy” rating and a 12-month price target of €12.00. The stock closed at €6.25 on March 6.Read More
Roth Capital Partners has resumed coverage of Viralytics (ASX:VLA; OTCQX:VRACY) with a “buy” rating and AUD$2 price target. The stock closed at AUD$1.05 on Jan. 30.Read More
3D Signatures (TSX-V:DXD) presented preliminary results of a collaborative initiative between the company and the Institut Universitaire de Cardiologie et de Pneumologie De Quebecd, exploring the possibility of identifying a biological marker to distinguish between two deadly forms of lung cancer, multiple synchronous lung adenocarcinoma (AC) and metastatic lung AC, which is a significant unmet clinical need in the management of patients with multiple lung lesions.Read More
GeneNews (TSX:GEN) has begun the process of introducing its portfolio of early cancer diagnostic tests to physicians in NeuHealth’s nationwide system of integrated physician networks (IPNs).
GeneNews’ partnership with NueHealth, announced in September 2016, is the first agreement from the company’s collaboration with JTS Health Partners (JTS).Read More
GeneNews (TSX:GEN) has entered into a partnership agreement with closely-held NueHealth, which delivers value-based healthcare solutions and connects patients directly to physicians through integrated provider networks.
Patients who access healthcare through NueHealth's provider networks will now be able to take advantage of three different screening tests: ColonSentry, earlyCDT-Lung and Prostate Health Index, which provide early risk stratification of colorectal, lung and prostate cancers.Read More
H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $3 price target. The stock closed at $1.30 on Monday.
Celsion has developed two cancer therapeutic platforms: LTSL for the delivery of chemotherapies and TheraPlas for the delivery of therapeutic DNA, RNA or proteins, both of which allow drugs to be delivered locally at high concentrations for greater therapeutic benefit and lower toxicity.Read More
ARIAD Pharmaceuticals (NASDAQ:ARIA) has reported updated clinical data for brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in patients who had experienced disease progression on crizotinib therapy.
The data show that, of patients on the 180 mg regimen (Arm B) with a median follow-up of 8.3 months, 54% achieved a confirmed objective response, the trial’s primary endpoint. In this arm, the median progression free survival exceeded one year (12.9 months) in this post-crizotinib setting.Read More
Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20.
The presentations are based on preclinical and clinical research conducted on the company’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel.Read More
Rodman & Renshaw has initiated coverage of VolitionRx (NASDAQ:VNRX) with a “buy” rating and a 12-month price target of $12. The stock closed at $3.77 on Friday.
“In our view, the company’s blood-based NuQ screening test for colorectal cancer, based on its proprietary nucleosomics epigenetic biomarker platform, is differentiated from traditional detection methods and other competing blood-based technologies in terms of accuracy, convenience and pricing,” writes analyst Yi Chen.Read More